By Denny Jacob
Danaher posted improved results across key metrics in its latest quarter, which it attributed to momentum in its bioprocessing unit and demand above expectations in its molecular diagnostics business.
The manufacturing conglomerate logged earnings of $954 million, or $1.32 a share, for the first quarter ended March 28, down from $1.09 billion, or $1.45 a share, in the prior-year period.
Stripping out certain one-time items, earnings came in at $1.88 a share. Analysts polled by FactSet had expected $1.63 a share.
Sales edged down to $5.74 billion from about $5.8 billion. Analysts polled by FactSet had expected $5.57 billion.
Chief Executive Rainer Blair said revenue, earnings and cash flow exceeded expectations, thanks to continued momentum in bioprocessing and better-than-expected respiratory demand in its molecular diagnostics business. He also noted that the macroeconomic backdrop has become more dynamic since the start of the year.
For the second quarter, Danaher forecast adjusted revenue to grow by low-single digits year-over-year. The company also guided for adjusted earnings per share of between $7.60 and $7.75 for 2025, in line with analysts' estimates.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
April 22, 2025 06:19 ET (10:19 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。